MiToS and King's staging as clinical outcome measures in ALS: A retrospective analysis of the FORTITUDE-ALS trial
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Open Access Publication
Rights and Permissions
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Chiò A, Andrews JA, Genge A, Jackson CE, Lechtzin N, Miller TM, Shefner JM. MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):304-310. doi: 10.1080/21678421.2022.2154678. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Gebrehiwet, Paulos; Meng, Lisa; Rudnicki, Stacy A; Sarocco, Phil; Wei, Jenny; Wolff, Andrew A; Chiò, Adriano; Andrews, Jinsy A; Genge, Angela; Jackson, Carlayne E; Lechtzin, Noah; Miller, Timothy M; and Shefner, Jeremy M, "MiToS and King's staging as clinical outcome measures in ALS: A retrospective analysis of the FORTITUDE-ALS trial." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24, 3-4. 304 - 310. (2023).
ICTS (Institute of Clinical and Translational Sciences)